<SEC-DOCUMENT>0001213900-17-007992-index.html : 20170728
<SEC-HEADER>0001213900-17-007992.hdr.sgml : 20170728
<ACCEPTANCE-DATETIME>20170728091705
ACCESSION NUMBER:		0001213900-17-007992
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20170727
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170728
DATE AS OF CHANGE:		20170728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		17988027

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k072817_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
Document 1 - file: f8k072817_actiniumpharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>f8k072817ex1i_actinium.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED AS OF JULY 28, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND OPPENHEIMER & CO. INC.. AS REPRESENTATIVE OF THE SEVERAL UNDERWRITERS PARTY THERETO
<TEXT>
Document 2 - file: f8k072817ex1i_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>f8k072817ex5i_actinium.htm
<DESCRIPTION>OPINION OF THE MATT LAW FIRM, PLLC.
<TEXT>
Document 3 - file: f8k072817ex5i_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>f8k072817ex10i_actinium.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
Document 4 - file: f8k072817ex10i_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>f8k072817ex99i_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED JULY 27, 2017
<TEXT>
Document 5 - file: f8k072817ex99i_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>f8k072817ex99ii_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED JULY 28, 2017.
<TEXT>
Document 6 - file: f8k072817ex99ii_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99i_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 7 - file: ex99i_001.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex99ii_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 8 - file: ex99ii_001.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex5i.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 9 - file: ex5i.jpg

</DOCUMENT>
</SEC-DOCUMENT>